Pharmaxis (ASX:PXS) will report on a review of Bronchitol® for the treatment of cystic fibrosis by an independent expert advisory panel to the U.S. Food and Drug Administration.
The Pulmonary-Allergy Drug Advisory Committee (PADAC), an independent expert advisory panel to the U.S. FDA will meet on Wednesday 30 January 2013 (U.S. time) to review Bronchitol®.
Until then Pharmaxis has requested a trading halt of its shares. The results are expected to be released on Thursday.
Bronchitol® was discovered and developed in Australia has been listed on the Pharmaceutical Benefits
Scheme (PBS) for the treatment of cystic fibrosis: one of the world’s most common life-shortening genetic diseases.
Bronchitol® (mannitol) is the first of a new class of cystic fibrosis medicines designed to tackle one of the fundamental problems that leads to loss of lung function.
It has been the subject of one of the largest clinical trial programs undertaken in cystic fibrosis - conducted in over 600 patients in 10 countries around the world and co-ordinated by scientists based in Australia.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX “Small and Mid-cap” stocks with distribution in Australia, UK, North America and Hong Kong / China.